- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Lyell Immunopharma Inc (LYEL)
The Lyell Immunopharma share price today is 20.720, view NASDAQ LYEL stock exchange data. Track the latest Lyell Immunopharma share price with real-time updates on LYEL stock performance including market cap, day range, 52-week range and dividend yield. Access LYEL charts, earnings dates and analyst estimates to support your investment decisions.
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
20.570
21.480
52 wk Range
7.650
45.000
LYEL is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
20.57021.480
52 wk Range
7.65045.000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
LYEL Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
37.167
Upside
+79.38%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Form S-3 Lyell Immunopharma Inc For: 3 April
- Investing.com
- Form 13G Lyell Immunopharma For: 21 April
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Strong Sell
Analyst Ratings
5 Buy
0 Hold
1 Sell
Ratings:
6 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 37.167
(+79.38% Upside)
Earnings
Latest Release
12-03-2026
EPS / Forecast
-6.86 / -0.17
Revenue / Forecast
6K / --
Compare LYEL to Peers and Sector
Metrics to compare | LYEL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLYELPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.8x | −3.1x | −0.5x | |
PEG Ratio | −0.05 | −0.09 | 0.00 | |
Price/Book | 1.9x | 2.4x | 2.6x | |
Price / LTM Sales | 13,429.2x | 7.4x | 3.3x | |
Upside (Analyst Target) | 97.0% | 369.7% | 47.1% | |
Fair Value Upside | Unlock | 14.9% | 6.2% | Unlock |
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Lyell Immunopharma (LYEL) Share Price Today?
The Lyell Immunopharma share price today is 20.720.
What is the current Lyell Immunopharma (LYEL) share price and day range?
As of 05-05-2026, the Lyell Immunopharma share price is 20.720, with a previous close of 20.720. The share price has ranged from 20.570 to 21.480 today, while the 52-week range spans from 7.650 to 45.000.
What Is the Lyell Immunopharma Market Cap?
As of today, Lyell Immunopharma market cap is 483.450M.
What Is the Lyell Immunopharma (LYEL) Share Price Target?
The average 12-month share price target for Lyell Immunopharma is 37.167, with a high estimate of 49 and a low estimate of 12. 5 analysts recommend buying, while 1 suggest selling, with an overall rating of Buy and +79.38% Upside potential.
What Is Lyell Immunopharma's Earnings Per Share (TTM)?
The Lyell Immunopharma EPS (TTM) is -16.056.
From a Technical Analysis Perspective, Is LYEL a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Lyell Immunopharma Trade On?
Lyell Immunopharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Lyell Immunopharma?
The stock symbol for Lyell Immunopharma is "LYEL."
How Many Times Has Lyell Immunopharma Stock Split?
Lyell Immunopharma has split 1 times.
How Many Employees Does Lyell Immunopharma Have?
Lyell Immunopharma has 300 employees.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.